Pfizer reports a significant drop in Paxlovid sales, leading to a decline in Q1 revenue, but reaffirms its full-year and 2025 guidance amid ongoing cost-saving initiatives.
Pfizer reports a significant drop in Paxlovid sales, leading to a decline in Q1 revenue, but reaffirms its full-year and 2025 guidance amid ongoing cost-saving initiatives.